1 hour ago
Xenon Pharmaceuticals (XENE) Plunges 25% on Psychiatric Trial Halt: Is Now the Time to Buy?
Xenon Pharmaceuticals (XENE) stock plummeted 25% after pausing psychiatric trials due to adverse events, though it filed for epilepsy drug approval.
The post Xenon Pharmaceuticals (XENE) Plunges 25% on Psychiatric Trial Halt: Is Now the Time to Buy? appeared first on Blockonomi.
Source: Blockonomi →Related News
- 25 minutes ago
Qorvo (QRVO) Stock Surges to 52-Week Peak Following $182M Bank of America Invest...
- 27 minutes ago
$7 Trillion Options Expiry: What September Triple Witching Means for Markets in...
- 27 minutes ago
AstraZeneca (AZN) Stock Gains Momentum Following CEO Share Purchase and European...
- 52 minutes ago
Nucor (NUE) Stock Tumbles 5% Following Weak Third Quarter Earnings Forecast
- 58 minutes ago
Steel Dynamics (STLD) Stock Drops 3.5% on Canadian Tariffs and Disappointing Q3...